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OBJECTIVE — To investigate whether parental family history of diabetes inﬂuences cardio-
vascular outcomes in type 2 diabetes.
RESEARCH DESIGN AND METHODS — We studied 1,294 type 2 diabetic patients
(mean age 64.1 years, 51.2% female) recruited to a community-based cohort study from
1993 to 1996 and followed until mid-2006. A data linkage system assessed all-cause and





family history was associated with earlier age of diabetes onset, and maternal family history was
associatedwithworseglycemiccontrol.Forallpatients,maternalfamilyhistorywassigniﬁcantly
associated with reduced risk of all-cause mortality and cardiac mortality. When analyzed by sex,
maternal family history had no effect on male patients, whereas female patients with diabetic
mothers had signiﬁcantly reduced hazard ratios for death from all causes (0.63 [95% CI 0.41–
0.96]; P  0.033), for death from cardiac causes (0.32 [0.14–0.72]; P  0.006), and for ﬁrst
myocardial infarction (0.45 [0.26–0.76]; P  0.003). Paternal family history status was not
associated with these outcomes.
CONCLUSIONS — A maternal family history of diabetes confers relative protection against
cardiovascular disease in female patients but not in male patients with type 2 diabetes. Paternal
family history is associated with risks equivalent to those without a family history of diabetes.
Some of the clinical heterogeneity of type 2 diabetes is related to maternal transmission effects
with differential impact on male and female patients.
Diabetes Care 33:1477–1483, 2010
T
hecomplexetiologyoftype2diabe-
tes involves both genetic compo-
nentsandenvironmentalexposures.
In type 2 diabetes, there is a well docu-
mented association between a family his-
tory of the disease and its development
(1,2). Maternal and paternal family histo-
ries of diabetes are both associated with
an earlier age of onset (2–4), and this ef-
fectismoremarkedwhenmultiplefamily
members are affected (5). In addition, in-
trauterine exposure to diabetes increases
theriskofdiabetesinoffspring(6),which
may help explain the reported excess ma-
ternal transmission (7,8).
Patients with familial diabetes have
relatively poor glycemic control, but few
other clinical differences have been re-
ported (4,5,9,10). An early age of onset
and poor glycemic control would both be
expected to have a negative impact on the
development of chronic complications,
but no such longitudinal data have been
published.Inthepresentstudy,weexam-
ined relationships among parental diabe-
tes and important clinical outcomes in
type 2 diabetes, including incident coro-
nary heart disease (CHD) and all-cause
and cardiac mortality in a large commu-
nity-based sample of patients with type 2
diabetes. We hypothesized that familial
diabetes would indicate worse clinical
outcomes. We investigated potential rela-
tionshipsinmaleandfemalepatientssep-




METHODS— The present sample
comprised all participants with type 2 di-
abetes enrolled in the Fremantle Diabetes
Study (FDS), a longitudinal observational
studyconductedfromapostcode-deﬁned
urban Australian community of 120,097
people.Descriptionsofrecruitment,sam-
ple characteristics including classiﬁcation
of diabetes type, and details of nonre-
cruited patients have been published pre-
viously (12,13). Of 2,258 diabetic
patients identiﬁed between 1993 and
1996, 1,426 (63%) were recruited and
1,294hadtype2diabetes.Thestudypro-
tocol was approved by the Fremantle
Hospital Human Rights Committee, and
all subjects gave informed consent before
participation.
Clinical assessment
Each participant underwent a compre-
hensive assessment at FDS entry that
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cluding questions on diabetes symptoms
at onset, self–glucose monitoring, atten-
dance at diabetes education/dietitian ses-
sions, lifestyle factors, education, self-
assessed ethnicity, ﬂuency with English,
and knowledge of diabetes (12); 2) a de-
tailed physical examination; and 3) the
provision of fasting blood and urine sam-
ples for automated biochemical tests per-
formedinasinglelaboratory.Aspartof1)
above, all participants were asked to pro-
vide details of relatives with known dia-
betes (including a speciﬁc enquiry as to
thestatusofmother,father,grandparents,
son, daughter, grandchildren, brother,
sister, uncle, aunt, and other) and their
respective diabetes treatment status
(whether insulin or tablet/diet treated).
Complications were identiﬁed using
standarddeﬁnitions(13).Peripheralneu-
ropathy was deﬁned as a score 2o f8o n
the Michigan Neuropathy Screening In-
strument clinical portion. Retinopathy
wastakenasanygradedetectedbydirect/
indirectophthalmoscopyand/orophthal-
mologist assessment. Nephropathy was
deﬁned as a ﬁrst-morning urinary albu-
min-to-creatinine ratio 3.0 mg/mmol.
Self-reported stroke/transient ischemic
attack were amalgamated with prior hos-
pitalizations to deﬁne baseline cerebro-
vascular disease status. Patients were
classiﬁed as having CHD if there was a
self-reported history of or hospitalization
for myocardial infarction, angina, revas-
cularization, or angioplasty. Peripheral
arterial disease was considered to be
present when the ankle-to-brachial index
was 0.90 or by the presence of a diabe-
tes-related amputation.
Incident cardiovascular disease and
mortality
The Hospital Morbidity Data System
records all public and private hospital
separations in Western Australia and, to-
gether with the death register, forms part
of the Western Australia Data Linkage
System (WADLS) (14). The FDS database
was linked with the WADLS to provide
morbidity/mortality data from 1 January
1993 until the end of June 2006. Hospi-
talizations for CHD and cerebrovascular
disease were extracted from WADLS to
calculate prevalent and incident myocar-
dial infarctions and strokes. The causes of
death were reviewed independently by
two of the authors (D.G.B. and T.M.E.D.)
and classiﬁed as being due to cardiac
causesornotunderthesystemusedinthe
UK Prospective Diabetes Study (15).
When there was disagreement between
raters, a ﬁnal consensus decision was
reached.
Statistical methods
Pancreatic -cell function and insulin
sensitivitywereestimatedfromfastingse-
rum glucose (FSG) and serum insulin
concentrations using homeostasis model
assessment (16). All data were analyzed
usingSPSSforWindows(version14.0.2).
Because GHb, FSG, serum triglycerides,
urinary albumin-to-creatinine ratio, insu-
lin sensitivity, and pancreatic -cell func-
tion were not normally distributed, they
were log-transformed before analysis.
Data are reported as means  SD, geo-
metric mean (SD range), medians
(interquartile range), or percentages.
ANOVAandFisher’sexacttestswereused
to test equality of means for normally dis-
tributed continuous and categorical vari-
ables, respectively. Variables with a
nonparametric distribution were ana-
lyzed using the Kruskal-Wallis test. If
differences were detected, pairwise com-
parison with a Student t test, Fisher exact
test, or Mann-Whitney test was under-
taken. Multivariate linear regression anal-
ysis was used to investigate effects on
glycemic and blood pressure control after
appropriate adjustment. Cox propor-
tional hazards modeling (with forward
conditional, variable entry, and removal
atP0.05and0.10,respectively)was
used to determine independent predic-
torsofall-causemortality,cardiacmortal-
ity, ﬁrst-time incident myocardial
infarction, and ﬁrst incident stroke (sub-
jects with prior events were excluded
from relevant models). All clinically plau-
sible variables were considered for entry




The patient sample was aged 64.1  11.3
years and 51.2% were women. A parental
family history of diabetes was reported by
397 patients (30.7%), of whom 264
(20.4%) had a maternal family history,
107 (8.3%) had a paternal family history,
and 26 (2.0%) had both parents affected
(Table 1). Diabetes onset occurred at a
signiﬁcantly younger age in patients with
parental diabetes. At the time of baseline
assessment, they were also younger but
had duration of diabetes similar to that of
patients without a family history. Patients
with a maternal family history had signif-
icantly higher FSG and GHb levels. Sys-
tolic blood pressure was lower with both
maternal and paternal family histories.
Afteradjustmentforage,diabetesdu-
ration, and treatment type, both FSG and
GHb remained signiﬁcantly higher with
maternal family history [ ln(FSG) 0.05
(95% CI 0.01–0.09) mmol/l; P  0.017
and ln(GHb) 0.05% (0.02–0.07); P 
0.001],butnotwithapaternalfamilyhis-
tory (P  0.39). After adjustment for age,
no signiﬁcant difference in systolic blood
pressure levels was seen with maternal or
paternal family histories. There were no
differences by family history in propor-
tions with GAD antibody positivity, pan-
creatic -cell function, or insulin
sensitivity, exercise levels, alcohol intake,
or proportions taking blood pressure–
lowering or lipid-lowering medications
(data not shown).
Family history, mortality,
myocardial infarction, and stroke
By the end of June 2006, crude all-cause
mortality rates were signiﬁcantly lower in
patients with maternal and paternal fam-
ily histories (Table 1). In Cox regression
models (Table 2), we examined the effect
of family history unadjusted (model 1),
after adjustment for age and sex (where
appropriate, model 2), and after adjust-
ment for identiﬁed relevant variables
(model 3, variables listed in supplemen-
tary Table 1, available in an online ap-
pendix at http://care.diabetesjournals.
org/cgi/content/full/dc10-0147/DC1). In
adjusted models, maternal or paternal
family history was entered into the most
parsimonious model to assess whether ei-
ther was an independent determinant of
outcome.Forallpatients,maternalfamily
history was associated with a signiﬁcantly
reduced risk of death from all causes and
from cardiac causes, whereas there was a
trend toward a reduction in the risk of
incident myocardial infarction (Table 2).
When analyzed by sex, the protective ef-
fect of maternal family history on all-
cause and cardiac mortality was only
signiﬁcant in female patients and was sig-
niﬁcantforincidentmyocardialinfarction
inwomen.Paternalfamilyhistorywasnot
associated with differences in clinical
outcomes.
Maternal family history, diabetes
presentation, and health-related
behaviors
To explore possible reasons for a protec-
tive effect of a maternal family history, we
assessed relationships with diabetes pre-
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edge of diabetes. No statistical differences
were found in mode of presentation at di-
agnosis (symptomatic or incidental), the
nature of the presenting symptoms
(thirst, polyuria, fatigue, weight loss, or
visual blurring), the frequency of medical
visits (family doctors, diabetes clinics, di-
abetesspecialists,diabeteseducators,and
other medical specialists), or in the per-
formance of self-monitoring of blood glu-
cose. Female patients with either parent
having diabetes had higher diabetes
knowledge scores than patients without a
family history (P  0.033), but this was
not seen in men with a parental family
history.
CONCLUSIONS— The results of
our longitudinal observational study are
consistent with those of previous reports
in showing that patients with a parental
family history of diabetes develop diabe-
tes 5 years before their counterparts
without a family history (2–5). We also
found that our patients with a maternal
family history had worse glycemic con-
trol. Despite these unfavorable features,
female patients with a maternal family
history had a lower risk of myocardial in-
farction and reduced all-cause and car-
diac mortality. Because women with type
2 diabetes have a substantially increased
risk of cardiovascular disease compared
with nondiabetic women (11), these data
suggest that diabetic women with a ma-
ternal family history have a risk of myo-
cardial infarction and death that is
intermediate between diabetic women
without a family history and nondiabetic
women. Male patients with a maternal
family history and patients of either sex
with a paternal family history had out-
comes comparable to those in patients
without a family history.
In explaining these ﬁndings, consid-
eration needs to be given to the relative
impact of maternal versus paternal family
history on cardiovascular disease in dia-
betes and why a beneﬁt should be con-
ﬁned to females. Familial disease can be
transmittedbygeneticandnongeneticin-
Table 1—Demographic and baseline clinical characteristics and subsequent crude mortality rates of the sample by parental family history
Family history
P No Maternal Paternal Both
n 897 264 107 26
Age (years) 65.5  10.8 61.4  11.7† 60.0  11.5† 58.0  11.8† 0.001
Age at diagnosis (years) 59.4  11.1 55.6  11.8† 53.1  12.5† 51.8  13.8† 0.001
Diabetes duration (years) 4.0 1.0–9.0 4.0 0.9–9.0 4.0 0.9–10.0 4.0 0.3–8.5 0.99
Male sex (%) 50.2 42.8 53.3 42.3 0.12
Ethnic background (%)
Anglo-Celt 65.6 56.1 63.6 57.7
Southern European 16.7 22.7 20.6 23.1
Other European 8.7 9.5 6.5 0.0 NV
Asian 2.7 2.7 5.6 19.2
Mixed/other 5.2 6.4 2.8 0.0
Indigenous 1.1 2.7 0.9 0.0
BMI (kg/m
2) 29.3  5.4 30.4  5.5† 30.0  5.3 29.6  5.4 0.019
Waist (% overweight/obese) 84.2 92.7† 87.6 80.8 0.002
Systolic blood pressure (mmHg) 152  24 148  22† 147  21† 146  23 0.009
Diastolic blood pressure (mmHg) 81  12 80  10 80  10 77  8 0.38
Fasting glucose (mmol/l) 8.2 6.8–10.6 8.9 7.2–11.7† 8.4 6.6–10.5 8.9 6.9–10.9 0.013
GHb (%) 7.3 6.3–8.7 7.96.7–9.2† 7.2 6.4–8.7 8.0 6.6–8.9 0.001
Diabetes treatment (%)
Diet alone 32.0 27.3 42.1 38.5
Oral agents 55.3 61.0 49.5 57.7 0.10
Insulin ( oral agents) 12.7 11.7 8.4 3.8
Total cholesterol (mmol/l) 5.5  1.2 5.5  1.0 5.5  1.0 5.5  1.2 0.97
HDL cholesterol (mmol/l) 1.06  0.33 1.05  0.30 1.08  0.35 1.10  0.33 0.80
Serum triglyceride (mmol/l) 1.9 (1.1–3.4) 1.9 (1.1–3.2) 2.0 (1.2–3.3) 1.7 (1.0–2.9) 0.72
Cerebrovascular disease (%) 11.6 7.2 6.5 3.8 0.08
CHD (%) 29.1 25.8 19.6 26.9 0.18
Peripheral arterial disease (%) 30.0 30.3 24.5 15.4 0.28
Retinopathy (%) 16.0 18.4 17.8 4.0 0.17
Neuropathy (%) 33.7 26.3* 23.3* 12.0* 0.005
Albumin-to-creatinine ratio (mg/mmol) 3.2 (0.7–13.7) 3.2 (0.8–13.1) 3.0 (0.5–16.7) 1.7 (0.6–4.7) 0.19
Smoking status (%)
Never smoked 45.1 46.9 33.3 52.0
Former smoker 39.9 37.0 51.4 40.0 0.20
Current smoker 15.0 16.0 15.2 8.0
All-cause mortality (%) 41.9 29.5† 34.0 11.5† 0.001
Cardiac mortality (%) 17.9 8.7† 10.4 7.7 0.001
Data are means  SD, geometric means (SD range), medians [interquartile range], or %. *P  0.05; †P  0.01 compared with no family history. NV, not valid.
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genetic mechanisms such as functional
imprinting and nonepigenetic mecha-
nisms such as familial behavioral and cul-
tural effects. With maternal transmission
of diabetes, additional mechanisms in-
clude intrauterine effects on fetal growth
and development that lead to persistent
changes in later life and transfer of mater-
Table 2—Hazard ratios for clinical outcomes in patients with type 2 diabetes by parental history

















All patients: maternal history
All-cause mortality
Model 1† 1,001 410 43.1 290 81 26.4 0.001 0.60 (0.48–0.77)
Model 2‡ 0.81 (0.64–1.03)
Model 3§ 0.69 (0.52–0.92)
Cardiac mortality
Model 1† 1,001 172 18.1 290 25 8.2 0.001 0.45 (0.30–0.69)
Model 2‡ 0.61 (0.40–0.93)
Model 3§ 0.50 (0.31–0.82)
Myocardial infarction
Model 1† 977 227 25.6 281 51 17.9 0.023 0.70 (0.52–0.95)
Model 2‡ 0.91 (0.67–1.24)
Model 3§ 0.73 (0.52–1.03)
Stroke
Model 1† 998 106 11.5 290 26 8.6 0.19 0.75 (0.49–1.15)
Model 2‡ 1.00 (0.65–1.54)
Model 3§ 0.73 (0.45–1.20)
All patients: paternal history
All-cause mortality
Model 1† 1,159 452 40.3 132 39 28.8 0.039 0.71 (0.51–0.98)
Model 2‡ 0.92 (0.66–1.28)
Model 3§ 1.06 (0.73–1.54)
Cardiac mortality
Model 1† 1,159 184 16.4 132 13 9.6 0.06 0.59 (0.33–1.03)
Model 2‡ 0.76 (0.43–1.34)
Model 3§ 0.96 (0.52–1.78)
Myocardial infarction
Model 1† 1,128 258 24.7 130 20 15.6 0.049 0.64 (0.40–1.00)
Model 2‡ 0.79 (0.50–1.25)
Model 3§ 0.98 (0.60–1.61)
Stroke
Model 1† 1,156 120 11.0 132 12 9.0 0.50 0.81 (0.45–1.47)
Model 2‡ 1.10 (0.61–2.00)
Model 3§ 1.15 (0.60–2.21)
Women: maternal history
All-cause mortality
Model 1† 495 179 36.9 166 41 22.8 0.004 0.61 (0.44–0.86)
Model 2‡ 0.81 (0.58–1.14)
Model 3§ 0.63 (0.41–0.96)
Cardiac mortality
Model 1† 495 77 15.9 166 10 5.6 0.001 0.35 (0.18–0.68)
Model 2‡ 0.47 (0.24–0.91)
Model 3§ 0.32 (0.14–0.72)
Myocardial infarction
Model 1† 485 104 22.6 161 23 13.7 0.029 0.61 (0.39–0.96)
Model 2‡ 0.83 (0.53–1.31)
Model 3§ 0.45 (0.26–0.76)
Stroke
Model 1† 495 52 11.0 166 14 7.9 0.27 0.72 (0.40–1.30)
Model 2‡ 0.93 (0.51–1.67)
Model 3§ 0.73 (0.40–1.36)
(continued)
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Model 1† 597 206 34.5 64 14 20.4 0.047 0.58 (0.34–1.00)
Model 2‡ 0.82 (0.48–1.42)
Model 3§ 1.20 (0.64–2.25)
Cardiac mortality
Model 1† 597 83 13.9 64 4 5.8 0.08 0.42 (0.15–1.14)
Model 2‡ 0.60 (0.22–1.65)
Model 3§ 0.79 (0.25–2.56)
Myocardial infarction
Model 1† 583 121 21.6 63 6 9.0 0.032 0.42 (0.19–0.95)
Model 2‡ 0.59 (0.26–1.34)
Model 3§ 0.62 (0.25–1.52)
Stroke
Model 1† 597 64 11.0 64 2 2.9 0.045 0.26 (0.06–1.07)
Model 2‡ 0.37 (0.09–1.50)
Model 3§ 0.40 (0.10–1.63)
Men: maternal history
All-cause mortality
Model 1† 506 231 49.6 124 40 31.5 0.006 0.63 (0.45–0.88)
Model 2‡ 0.80 (0.57–1.12)
Model 3§ 0.78 (0.53–1.14)
Cardiac mortality
Model 1† 506 95 20.4 124 15 11.8 0.044 0.58 (0.33–0.99)
Model 2‡ 0.74 (0.43–1.29)
Model 3§ 0.70 (0.39–1.27)
Myocardial infarction
Model 1† 492 123 28.8 120 28 23.9 0.40 0.84 (0.56–1.26)
Model 2‡ 0.99 (0.65–1.50)
Model 3§ 0.92 (0.60–1.42)
Stroke
Model 1† 503 54 12.0 124 12 9.6 0.48 0.80 (0.43–1.49)
Model 2‡ 1.07 (0.57–2.01)
Model 3§ 0.90 (0.47–1.75)
Men: paternal history
All-cause mortality
Model 1† 562 246 46.7 68 25 37.5 0.30 0.80 (0.53–1.21)
Model 2‡ 0.96 (0.63–1.46)
Model 3§ 1.03 (0.64–1.66)
Cardiac mortality
Model 1† 562 101 19.2 68 9 13.5 0.31 0.71 (0.36–1.39)
Model 2‡ 0.84 (0.42–1.68)
Model 3§ 0.87 (0.41–1.81)
Myocardial infarction
Model 1† 545 137 28.4 67 14 22.9 0.45 0.81 (0.47–1.40)
Model 2‡ 0.91 (0.52–1.59)
Model 3§ 0.98 (0.55–1.75)
Stroke
Model 1† 559 56 11.0 68 10 15.4 0.33 1.40 (0.71–2.74)
Model 2‡ 1.75 (0.88–3.45)
Model 3§ 1.61 (0.79–3.26)
*Events per 1,000 person-years. †Model 1 is unadjusted. ‡Model 2 includes age and sex (where applicable). §Model 3 includes all variables in the respective most
parsimonious models (supplementary Table 1).
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The present study included the assess-
mentofarangeofbiological,lifestyle,and
behavioral factors, but we found no can-
didateexplanatoryvariablesamongthem.
Lower baseline systolic blood pressure
levels were seen with maternal and pater-
nal family histories, but this effect did not
persist after age adjustment. A study in
Taiwanese patients found that a parental
family history of diabetes conferred a
lower risk of hypertension in type 2 dia-
betes (17), suggesting that further study
of blood pressure control in relation to
family history would be worthwhile. The
women with diabetic parents in the
presentstudyhadbetterknowledgeofdi-
abetes, but the women with a paternal
familyhistoryalsohadgreaterknowledge
without evident beneﬁt, although there is
evidence that knowledge alone does not
inﬂuence cardiovascular outcomes in di-
abetes (18). Despite these negative ﬁnd-
ings, we cannot rule out the possibility
that behavior related to family history
mayexplaintheresults.Forinstance,sub-
jects with a family history may be more
likely to recognize the risk factors and
symptoms of diabetes and thus receive a
diagnosis and start appropriate manage-
ment(includingthatfornonglycemiccar-
diovascular risk factors) at a relatively
early stage.
We were not able to collect valid data
on the age of onset of diabetes in the
mothers, but the great majority are likely
to have had type 2 diabetes. Human and
animalstudieshavedemonstratedthatfe-
tal exposure to maternal diabetes leads to
a higher prevalence of impaired glucose
tolerance in the offspring largely related
to insulin secretory defects (6,8). More
than 70% of women with gestational dia-
betes mellitus develop type 2 diabetes
when followed for 10 years, and many
womenwhodevelopdiabetesbuthadnot
received a diagnosis of gestational diabe-
tes mellitus are likely to have had some
degree of glucose intolerance when preg-
nant (19,20). Therefore, in the present
study, there may have been prenatal
changes induced by maternal glucose in-
tolerance in a proportion of patients with
maternal family history. Because this
mode of transmission of diabetogenic
traits is also associated with adverse car-
diovascular risk factors in offspring dur-
ing early life (8,10,21), the present data
indicate that there are qualitative differ-
encesinthecardiovascularriskthatresult
from prenatal maternal factors compared
with that seen in nonfamilial type 2 dia-
betes. One possible explanation is that fe-
tal diabetogenic factors persist, whereas
fetal nonglycemic cardiovascular risk fac-
tors wane with age.
There are several potential explana-
tions as to why maternal family history
hadadifferentialeffectinmaleandfemale
patients. There are increasing reports of
sex differences resulting from genetic and
epigenetictransmissioninarangeofcom-
mon complex disorders, including car-
diovascular disease and type 2 diabetes
(8,22). For example, sex differences were
reported in an animal model of fetal im-
printing in which male offspring devel-
oped hypertension, but females were
protected(23).Itisalsopossiblethatmen
give less accurate family histories, al-
though studies on the analytical validity
of family history reports do not indicate a
sex bias (24).
The study strengths include the large
and representative nature of the sample,
the detailed nature of clinical and demo-
graphic assessment, and the complete-
nessofascertainmentofthemajorclinical
end points using a well-validated data
linkage system. The major limitation re-
lates to the method used to assess family
history. Patients classiﬁed as having no
family history of diabetes included those
with limited or no knowledge of the
health status of their relatives. This may
have led to instances of a false-negative
family history and thus an overestimation
of the maternal transmission of diabetes
because an unknown paternal status is
more common in this situation (25).
Other potential limitations include recall
bias for family history, demonstrated to
be minimal in diabetes (24), and a lack of
statistical power to detect effects from pa-
ternal family history as the number of af-
fected patients was relatively small. We
were unable to distinguish gestational di-
abetes mellitus or the time of onset in the
parents with diabetes and the study did
not take account of other relevant family
history such as having affected siblings.
In summary, the present study dem-
onstratesthatwomenwithtype2diabetes
and a maternal family history of diabetes
have a lower risk of myocardial infarction
and death from cardiac causes than
women without a family history of diabe-
tes. These data indicate another source of
heterogeneity in the clinical impact of
type2diabetesandhaverelevanceforun-
derstanding the pathophysiology, epide-
miology, and public health impact of
cardiovascular disease in women with
type 2 diabetes.
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